Magnova 1000 mg/125 mg Injection is a combination antibiotic formulation containing Cefepime, a fourth-generation cephalosporin (1000 mg), and Tazobactam, a β-lactamase inhibitor (125 mg). This injectable preparation is indicated for the treatment of moderate to severe bacterial infections caused by susceptible organisms, including complicated urinary tract infections, intra-abdominal infections, skin and soft tissue infections, and pneumonia. Cefepime exerts its bactericidal action by inhibiting bacterial cell wall synthesis, leading to cell lysis and death, while Tazobactam enhances efficacy by inhibiting β-lactamase enzymes produced by resistant bacteria, thereby extending the spectrum of activity. Magnova is effective against a broad range of gram-positive and gram-negative pathogens, including Pseudomonas aeruginosa and Enterobacteriaceae. The injection is administered intravenously or intramuscularly, with dosage adjustments recommended in patients with renal impairment. Common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and transient hematologic abnormalities. Caution is advised in patients with a history of β-lactam allergy. Magnova 1000 mg/125 mg Injection should be used under strict medical supervision, with therapy guided by culture and sensitivity results to minimize the development of resistance and ensure optimal clinical outcomes.